WHO Drug Information Vol. 15, No. 2, 2001
(2001; 91 pages) View the PDF document
Table of Contents
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters
View the documentNew Zealand and Australia: joint medicines regulatory body
View the documentBupropion safety information
View the documentBupropion update
View the documentItraconazole and congestive heart failure
View the documentTerbinafine and hepatic failure
View the documentPaediatric amiodarone labelling changes
View the documentCerivastatin: marketing discontinued
View the documentPhenylpropanolamine withdrawn from market
View the documentCounterfeit filgrastim
View the documentOxycodone: strengthened warning
View the documentNesiritide for heart failure
View the documentOprelvekin: paediatric safety information
View the documentPeginterferon alfa-2b combined use: new labelling
View the documentRibavirin for combined use
View the documentSleep attacks with pramipexole and ropinirole
View the documentRosiglitazone-associated hepatic and cardiovascular events
View the documentClarithromycin: labelling change
View the documentHerbal OTC remedy and hepatic dysfunction
View the documentAntipsychotics and high prolactin
View the documentSildenafil: not for use with nitrates
View the documentPropofol, heart failure and high dosages
View the documentBupropion and seizures
View the documentNeurotoxicity with aciclovir and valaciclovir
View the documentRevised labelling for levocarnitine
View the documentAvoid trastuzumab and anthracyclines
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsEssential Drugs
Open this folder and view contentsRecent Publications and Sources of Information
View the documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentDénominations communes internationales des Substances pharmaceutiques (DCI)
View the documentDenominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)
View the documentAmendments to previous lists/Modifications apportées aux listes antérieures/Modificaciones a las listas anteriores
View the documentAnnexes
 

Neurotoxicity with aciclovir and valaciclovir

Sweden - Reports of central nervous system disorders, including confusion, hallucinations, psychosis, agitation, seizures, and impaired coordination, have been made to the Swedish adverse drug reactions data base at the Medicines Products Agency.

Many of the affected patients had renal insufficiency and most were aged over 60 years of age. Approximately half the patients with renal insufficiency who experienced CNS effects received higher than recommended dosages of the drugs; the product information states that the dosage should be adjusted to a patient’s degree of renal insufficiency. Concomitant psychoactive medications could also be a risk factor. Such adverse reactions can be treated with haemodialysis, which results in symptomatic improvement.

Reference: Medicines Products Agency, 12: 30, February 2001.

to previous section to next section
 

Last updated: May 3, 2013